Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer

Pioneering Evidence-Based AI Innovation in Personalized Wellness and Health Research

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs' commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.

Dr. Gagnier brings highly credentialed academic and clinical epidemiology leadership to Fifty1 AI Labs. With a Doctor of Naturopathic Medicine (ND) from the Canadian College of Naturopathic Medicine, an MSc and PhD in Clinical Epidemiology & Biostatistics from the University of Toronto, and a post-doctoral fellowship in Epidemiologic Methods at the University of Michigan, he currently serves as Associate Professor in both Epidemiology & Biostatistics and Surgery at Western University's Schulich School of Medicine & Dentistry. As Field Leader of the Clinical Epidemiology & Research Management master's program, Dr. Gagnier has trained the next generation of health researchers. His formal, advanced training establishes strong scientific legitimacy for Fifty1AI Labs, signaling to investors and partners that the company is dedicated to high-quality, evidence-based health research rather than superficial wellness marketing.

A recognized expert in clinical trial methodology, systematic reviews, meta-analyses, outcome measurement, and reporting standards—particularly for patient-reported outcome measures (PROMs), bias assessment, and measurement scale validation—Dr. Gagnier has focused his research on enhancing the properties of health outcome scales, reducing bias in PROMs, and improving trial reporting consistency. This expertise ensures that Fifty1 AI Labs' data and insights are replicable, transparent, and rigorous, providing a key differentiator in risk mitigation, regulatory acceptance, and credibility with customers and collaborators.